Go Pro
→ Why major institutions are piling into this digital asset now (From Awesomely) (Ad)tc pixel Free SYRE Stock Alerts

Spyre Therapeutics (SYRE) Financials

Spyre Therapeutics logo
$106.65 +0.16 (+0.15%)
Closing price 04:00 PM Eastern
Extended Trading
$107.51 +0.86 (+0.81%)
As of 04:34 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Spyre Therapeutics

Annual Income Statements for Spyre Therapeutics

This table shows Spyre Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -12 -22 -27 -44 -78 -81 -66 -84 -339 -208 -155
Consolidated Net Income / (Loss)		 -11 -22 -27 -44 -78 -81 -66 -84 -339 -208 -155
Net Income / (Loss) Continuing Operations		 -11 -22 -27 -44 -78 -81 -66 -84 -339 -208 -155
Total Pre-Tax Income 		-11 -22 -27 -44 -78 -81 -66 -84 -339 -208 -155
Total Operating Income		 -11 -22 -28 -45 -80 -81 -66 -85 -242 -209 -210
Total Gross Profit		 6.09 4.63 5.21 3.89 0.00 0.00 19 2.33 0.89 0.00 0.00
Total Revenue		 6.09 4.63 5.21 3.89 0.00 0.00 19 2.33 0.89 0.00 0.00
Operating Revenue		 6.09 4.63 5.21 3.89 0.00 0.00 19 2.33 0.89 0.00 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 17 27 33 49 80 81 84 87 243 209 210
Selling, General & Admin Expense		 5.95 8.39 10 13 16 22 27 29 40 46 48
Research & Development Expense		 11 18 23 37 65 60 57 59 220 163 172
Other Operating Expenses / (Income)		 - - - - - - 0.00 0.00 -16 0.00 -10
Total Other Income / (Expense), net		 0.02 0.21 0.44 1.12 2.08 0.59 -0.01 0.84 -97 0.60 54
Interest & Investment Income		 0.02 0.24 0.48 1.17 2.14 0.59 0.11 0.84 6.15 21 25
Other Income / (Expense), net		 -0.00 -0.04 -0.04 -0.06 -0.06 -0.01 -0.12 0.00 -103 -21 29
Income Tax Expense		 - - - - 0.00 0.00 0.14 -0.14 -0.03 0.05 -0.02
Basic Earnings per Share		 ($19.21) ($2.22) ($1.80) ($2.13) ($2.45) ($1.52) $0.00 $0.00 ($1,114.33) $0.00 ($160.02)
Weighted Average Basic Shares Outstanding		 599.79K 9.79M 15.13M 20.82M 31.95M 53.37M 2.63M 0.00 7.34M 0.00 64.42M
Diluted Earnings per Share		 ($19.21) ($2.22) ($1.80) ($2.13) ($2.45) ($1.52) $0.00 $0.00 ($1,114.33) $0.00 ($160.02)
Weighted Average Diluted Shares Outstanding		 599.79K 9.79M 15.13M 20.82M 31.95M 53.37M 2.63M 0.00 7.34M 0.00 64.42M
Weighted Average Basic & Diluted Shares Outstanding		 599.79K 9.79M 15.13M 20.82M 31.95M 53.37M 65.74M 65.40M 36.15M 60.28M 78.54M

Quarterly Income Statements for Spyre Therapeutics

This table shows Spyre Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -63 -44 -39 -69 -56 -45 -37 -11 -63 -69 -36
Consolidated Net Income / (Loss)		 -63 -44 -39 -69 -56 -45 -37 -11 -63 -69 -36
Net Income / (Loss) Continuing Operations		 -63 -44 -39 -69 -56 -45 -37 -11 -63 -69 -36
Total Pre-Tax Income 		-63 -44 -39 -69 -56 -45 -37 -11 -63 -69 -36
Total Operating Income		 -46 -48 -44 -55 -61 -54 -42 -57 -57 -46 -42
Total Gross Profit		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Cost of Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Operating Expenses		 46 48 44 55 61 54 42 57 57 46 42
Selling, General & Admin Expense		 14 13 12 11 11 12 12 12 13 15 16
Research & Development Expense		 34 35 33 45 50 42 40 45 45 60 66
Other Operating Expenses / (Income)		 - - 0.00 0.00 - 0.00 -10 0.00 - -30 -40
Total Other Income / (Expense), net		 -17 3.95 5.31 -14 4.96 8.78 5.22 46 -5.36 -23 5.44
Interest & Investment Income		 4.13 4.43 5.92 5.18 5.78 6.49 5.87 5.38 7.14 7.00 10
Other Income / (Expense), net		 -21 -0.48 -0.61 -19 -0.82 2.29 -0.66 40 -12 -30 -4.61
Income Tax Expense		 - 0.03 0.00 0.02 0.00 -0.02 0.00 0.00 - 0.00 0.00
Basic Earnings per Share		 ($8.61) ($58.58) $0.00 $0.00 ($1.19) ($48.50) $0.00 ($12.09) ($59.70) $0.00 ($29.56)
Weighted Average Basic Shares Outstanding		 7.34M 37.12M 0.00 0.00 47.49M 60.63M 0.00 60.78M 64.42M 0.00 85.09M
Diluted Earnings per Share		 ($8.61) ($58.58) $0.00 $0.00 ($1.19) ($48.50) $0.00 ($12.09) ($59.70) ($0.74) ($29.56)
Weighted Average Diluted Shares Outstanding		 7.34M 37.12M 0.00 0.00 47.49M 60.63M 0.00 60.78M 64.42M 0.00 85.09M
Weighted Average Basic & Diluted Shares Outstanding		 36.15M 40.28M 50.79M 51.43M 60.28M 60.35M 60.40M 77.59M 78.54M 86.84M 88.17M

Annual Cash Flow Statements for Spyre Therapeutics

This table details how cash moves in and out of Spyre Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 27 18 -35 9.64 -1.71 71 -75 19 153 -100 -3.70
Net Cash From Operating Activities		 -11 -19 -25 -32 -66 -76 -54 -80 -100 -157 -169
Net Cash From Continuing Operating Activities		 -11 -19 -25 -32 -66 -76 -54 -80 -100 -157 -169
Net Income / (Loss) Continuing Operations		 -11 -22 -27 -44 -78 -81 -66 -84 -339 -208 -155
Consolidated Net Income / (Loss)		 -11 -22 -27 -44 -78 -81 -66 -84 -339 -208 -155
Depreciation Expense		 0.09 0.13 0.25 0.29 0.42 1.00 1.58 1.57 0.74 0.00 0.00
Amortization Expense		 0.00 0.10 0.08 -0.59 -0.82 0.07 0.97 0.07 -2.10 -11 -8.09
Non-Cash Adjustments To Reconcile Net Income		 1.56 1.18 2.50 5.25 5.86 6.59 7.70 7.10 243 67 -0.03
Changes in Operating Assets and Liabilities, net		 -1.33 1.45 -0.20 7.20 7.10 -2.54 1.83 -5.07 -2.88 -4.53 -5.93
Net Cash From Investing Activities		 -4.01 -12 -23 -15 -1.74 -7.60 -23 57 -108 -353 -143
Net Cash From Continuing Investing Activities		 -4.01 -12 -23 -15 -1.74 -7.60 -23 57 -108 -353 -143
Purchase of Investments		 -3.77 -20 -64 -62 -92 -129 -133 -40 -167 -599 -522
Sale of Property, Plant & Equipment		 - - - - - - 0.00 0.00 0.48 0.00 0.00
Divestitures		 - - - - - - 0.00 0.00 18 0.00 7.00
Sale and/or Maturity of Investments		 - 8.45 42 47 92 126 111 97 40 246 372
Net Cash From Financing Activities		 42 49 12 57 66 155 1.39 43 361 411 309
Net Cash From Continuing Financing Activities		 42 49 12 57 66 155 1.39 43 361 411 309
Repayment of Debt		 - - - - - - - - -0.02 0.00 0.00
Issuance of Common Equity		 0.02 49 0.83 3.02 66 155 1.90 43 367 413 314
Other Financing Activities, net		 - - 11 54 -0.03 -0.02 -0.51 -0.42 -5.79 -1.84 -5.41
Other Net Changes in Cash		 - - - - - 0.05 - -0.11 0.03 -0.00 0.00

Quarterly Cash Flow Statements for Spyre Therapeutics

This table details how cash moves in and out of Spyre Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 97 39 -182 26 18 -41 33 -17 21 11 65
Net Cash From Operating Activities		 -31 -29 -62 -29 -37 -41 -47 -37 -45 -57 -70
Net Cash From Continuing Operating Activities		 -31 -29 -62 -29 -37 -41 -47 -37 -45 -57 -70
Net Income / (Loss) Continuing Operations		 -63 -44 -39 -69 -56 -45 -37 -11 -63 -69 -36
Consolidated Net Income / (Loss)		 -63 -44 -39 -69 -56 -45 -37 -11 -63 -69 -36
Amortization Expense		 -1.71 -2.42 -3.56 -3.00 -2.42 -2.64 -2.01 -1.35 -2.09 -2.06 -3.09
Non-Cash Adjustments To Reconcile Net Income		 36 14 9.31 32 11 6.99 1.21 -31 22 13 -22
Changes in Operating Assets and Liabilities, net		 -1.86 3.47 -29 10 11 -0.57 -9.04 5.94 -2.27 0.24 -9.01
Net Cash From Investing Activities		 -35 -105 -121 43 -171 -0.06 79 25 -247 57 -298
Net Cash From Continuing Investing Activities		 -35 -105 -121 43 -171 -0.06 79 25 -247 57 -298
Purchase of Investments		 -54 -153 -178 -35 -233 -71 -35 -74 -342 -81 -447
Divestitures		 - - - - - 0.00 - - - 30 40
Sale and/or Maturity of Investments		 19 48 58 78 63 71 107 99 94 108 109
Net Cash From Financing Activities		 164 172 0.36 13 226 0.13 0.73 -4.64 313 12 433
Net Cash From Continuing Financing Activities		 164 172 0.36 13 226 0.13 0.73 -4.64 313 12 433
Issuance of Common Equity		 367 174 0.50 13 395 0.22 0.73 0.49 313 12 456
Other Financing Activities, net		 -5.79 -1.43 - -0.08 -0.33 -0.09 - -5.13 -0.07 -0.17 -23

Annual Balance Sheets for Spyre Therapeutics

This table presents Spyre Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 39 67 56 78 83 162 110 71 342 608 778
Total Current Assets		 38 66 55 77 75 150 99 62 342 608 778
Cash & Equivalents		 29 48 13 22 19 90 15 35 189 89 86
Short-Term Investments		 3.77 16 37 52 53 56 78 21 150 514 671
Prepaid Expenses		 0.91 1.71 1.61 2.16 2.56 3.52 4.95 6.17 2.25 5.39 21
Plant, Property, & Equipment, net		 0.35 0.60 0.85 1.02 2.39 5.64 4.55 3.22 0.00 0.00 0.00
Total Noncurrent Assets		 0.02 0.04 0.23 0.05 6.29 6.19 6.49 5.67 0.33 0.01 0.00
Total Liabilities & Shareholders' Equity		 39 67 56 78 83 162 110 71 342 608 778
Total Liabilities		 2.55 4.10 5.74 10 23 22 26 21 73 91 63
Total Current Liabilities		 2.52 3.97 5.63 10 18 16 20 15 32 54 59
Accounts Payable		 0.18 0.17 0.39 0.66 3.15 2.25 3.32 0.68 17 1.27 8.92
Accrued Expenses		 2.35 3.73 5.22 9.58 15 14 14 13 13 28 27
Other Current Liabilities		 - - - - 0.35 0.32 0.44 0.63 1.39 25 23
Total Noncurrent Liabilities		 0.03 0.13 0.11 0.07 4.74 5.34 5.84 6.18 41 37 3.86
Other Noncurrent Operating Liabilities		 - - - - 4.71 5.13 4.61 4.00 41 37 3.86
Other Noncurrent Nonoperating Liabilities		 0.03 0.13 0.11 0.07 0.03 0.21 0.02 - - - 0.00
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -22 63 50 67 60 140 84 50 184 518 715
Total Preferred & Common Equity		 -22 63 50 67 60 140 84 50 184 518 715
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 185 156 156
Total Common Equity		 -22 63 50 67 60 140 84 50 -0.91 362 559
Common Stock		 1.37 108 123 184 255 416 426 476 763 1,334 1,686
Retained Earnings		 -24 -45 -73 -117 -195 -276 -342 -426 -764 -972 -1,128
Accumulated Other Comprehensive Income / (Loss)		 -0.00 -0.00 -0.10 -0.03 0.05 0.01 -0.02 -0.05 0.30 0.18 0.87

Quarterly Balance Sheets for Spyre Therapeutics

This table presents Spyre Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 52 244 207 488 436 421 570 539 505 764 1,173
Total Current Assets		 44 240 206 487 436 421 570 539 505 764 1,173
Cash & Equivalents		 35 235 91 228 45 72 48 82 65 97 162
Short-Term Investments		 3.24 0.00 113 257 381 343 516 445 421 644 983
Prepaid Expenses		 5.57 2.88 2.19 2.63 9.74 6.85 4.95 12 18 22 28
Plant, Property, & Equipment, net		 3.42 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Noncurrent Assets		 4.65 3.64 1.32 0.33 0.33 0.01 0.01 0.00 0.00 0.00 0.00
Total Liabilities & Shareholders' Equity		 52 244 207 488 436 421 570 539 505 764 1,173
Total Liabilities		 19 254 66 82 62 94 87 83 50 93 72
Total Current Liabilities		 13 232 45 43 22 58 71 83 46 85 63
Accounts Payable		 2.06 24 22 19 14 20 6.24 3.74 11 5.74 5.77
Accrued Expenses		 9.67 28 16 22 5.68 13 22 19 24 29 26
Other Current Liabilities		 0.61 179 7.51 2.59 2.64 25 43 60 11 50 31
Total Noncurrent Liabilities		 6.16 21 21 39 40 36 16 0.00 3.23 7.98 8.56
Other Noncurrent Operating Liabilities		 3.82 0.00 21 39 40 36 16 0.00 3.23 6.69 7.27
Other Noncurrent Nonoperating Liabilities		 - 19 - - - - - - - 1.29 1.29
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 34 -207 -245 152 374 327 483 456 455 671 1,101
Total Preferred & Common Equity		 34 -207 -245 152 374 327 483 456 455 671 1,101
Preferred Stock		 0.00 0.00 0.00 185 156 156 156 156 156 156 146
Total Common Equity		 34 -207 -245 -33 219 172 327 300 299 515 955
Common Stock		 478 454 456 776 1,066 1,086 1,343 1,353 1,364 1,712 2,190
Retained Earnings		 -444 -661 -701 -808 -847 -916 -1,017 -1,054 -1,065 -1,197 -1,233
Accumulated Other Comprehensive Income / (Loss)		 -0.01 0.01 -0.13 -0.36 -0.55 1.46 0.68 0.45 0.79 -0.77 -2.40

Annual Metrics And Ratios for Spyre Therapeutics

This table displays calculated financial ratios and metrics derived from Spyre Therapeutics' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% -23.94% 12.47% -25.30% -100.00% 0.00% 0.00% -87.57% -61.96% -100.00% 0.00%
EBITDA Growth		 -26.35% -93.38% -26.19% -67.26% -76.34% 0.47% 21.38% -31.51% -316.53% 30.50% 21.81%
EBIT Growth		 -27.10% -93.89% -26.32% -64.23% -76.62% -1.35% 19.29% -28.90% -306.89% 33.54% 21.45%
NOPAT Growth		 -27.08% -93.60% -26.34% -64.27% -76.70% -1.43% 19.43% -29.14% -185.80% 13.92% -0.48%
Net Income Growth		 -9.16% -92.10% -25.52% -62.83% -76.45% -3.37% 18.66% -27.38% -304.21% 38.60% 25.39%
EPS Growth		 75.17% 88.44% 18.92% -18.33% -15.02% 37.96% 18.66% -27.38% 0.00% 76.88% 0.00%
Operating Cash Flow Growth		 -49.72% -71.55% -30.65% -30.79% -104.06% -15.35% 29.11% -49.20% -24.66% -57.55% -7.52%
Free Cash Flow Firm Growth		 0.00% -9.46% -66.87% -23.77% -108.46% -21.86% 31.34% -46.74% -65.28% -25.99% -45.09%
Invested Capital Growth		 0.00% -113.52% 136.88% -4,806.71% -68.79% 47.39% -47.28% 41.05% -1,207.92% -20.62% 51.58%
Revenue Q/Q Growth		 0.00% -6.81% 4.75% -27.61% 0.00% 0.00% 24.14% -59.88% -15.94% 0.00% 0.00%
EBITDA Q/Q Growth		 0.00% -7.65% -4.21% -24.31% -8.54% -0.47% 4.10% 1.38% -16.95% 1.84% -4.01%
EBIT Q/Q Growth		 0.00% -7.77% -4.05% -23.60% -8.95% -1.03% 3.38% 1.51% -16.22% 2.23% -4.40%
NOPAT Q/Q Growth		 0.00% -7.59% -4.08% -23.59% -8.96% -1.08% 3.43% 1.49% -12.41% -7.94% 1.91%
Net Income Q/Q Growth		 0.00% -7.41% -3.81% -23.42% -9.21% -1.53% 3.33% 1.90% -15.07% 3.20% -4.18%
EPS Q/Q Growth		 0.00% 84.71% -141.00% -13.90% -0.41% -18.75% 3.33% 1.90% -1,525.10% -6,004.27% -6,431.43%
Operating Cash Flow Q/Q Growth		 0.00% -25.38% -5.24% -4.30% -16.07% -1.12% -4.14% 1.39% -14.82% -4.07% -4.56%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% -8.88% 0.96% -17.60% -1.71% -5.05% 2.10% -9.67% -19.13% 7.12%
Invested Capital Q/Q Growth		 0.00% -313.76% 220.16% -620.76% -33.50% -68.21% 11.37% 11.68% -14.23% 1.79% -32.80%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 0.00% 0.00% 100.00% 100.00% 100.00% 0.00% 0.00%
EBITDA Margin		 -184.49% -469.08% -526.30% -1,178.50% 0.00% 0.00% -337.38% -3,569.94% -39,087.70% 0.00% 0.00%
Operating Margin		 -185.95% -473.34% -531.72% -1,169.32% 0.00% 0.00% -350.33% -3,640.23% -27,347.97% 0.00% 0.00%
EBIT Margin		 -185.98% -474.11% -532.53% -1,170.78% 0.00% 0.00% -350.98% -3,640.23% -38,934.88% 0.00% 0.00%
Profit (Net Income) Margin		 -185.62% -468.84% -523.27% -1,140.64% 0.00% 0.00% -351.14% -3,598.75% -38,238.15% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.21% 99.84% 99.99% 100.02% 99.99%
Interest Burden Percent		 99.81% 98.89% 98.26% 97.43% 97.33% 99.27% 99.83% 99.02% 98.22% 90.70% 86.18%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -529.98% -1,186.40% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 -509.60% -1,173.21% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 467.41% 1,142.60% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -62.57% -43.80% -48.08% -75.32% -122.74% -80.93% -58.81% -124.87% -212.49% -52.91% -25.17%
Cash Return on Invested Capital (CROIC)		 -729.98% 0.00% -13,373.29% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -29.28% -41.51% -45.02% -68.03% 0.00% 0.00% -48.44% -93.64% -167.05% 0.00% 0.00%
Return on Assets (ROA)		 -29.22% -41.05% -44.24% -66.28% 0.00% 0.00% -48.46% -92.58% -164.06% 0.00% 0.00%
Return on Common Equity (ROCE)		 38.49% -18.02% -48.08% -75.32% -122.74% -80.93% -58.81% -124.87% -32.91% -24.29% -18.81%
Return on Equity Simple (ROE_SIMPLE)		 50.86% -34.46% -54.11% -65.77% -130.25% -57.85% -78.39% -166.61% -184.11% -40.17% 0.00%
Net Operating Profit after Tax (NOPAT)		 -7.92 -15 -19 -32 -56 -57 -46 -59 -170 -146 -147
NOPAT Margin		 -130.16% -331.34% -372.20% -818.52% 0.00% 0.00% -245.23% -2,548.16% -19,143.58% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -20.38% -13.19% -13.85% -20.10% -30.09% -21.89% -16.60% -32.88% -85.66% -13.16% -1.25%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -117.97% -92.17% -28.20% -20.51%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 97.73% 181.31% 193.39% 324.90% 0.00% 0.00% 145.79% 1,225.03% 4,508.58% 0.00% 0.00%
R&D to Revenue		 188.22% 392.03% 438.33% 944.42% 0.00% 0.00% 304.55% 2,515.20% 24,795.94% 0.00% 0.00%
Operating Expenses to Revenue		 285.95% 573.34% 631.72% 1,269.32% 0.00% 0.00% 450.33% 3,740.23% 27,447.97% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -11 -22 -28 -46 -80 -81 -66 -85 -345 -229 -180
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -11 -22 -27 -46 -81 -80 -63 -83 -346 -241 -188
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 23.20 44.72 66.54 92.15 67.45 69.77 13.75 0.00 3.31 4.54
Price to Tangible Book Value (P/TBV)		 0.00 23.20 44.72 66.54 92.15 67.45 69.77 13.75 0.00 3.31 4.54
Price to Revenue (P/Rev)		 0.00 315.60 432.50 1,154.04 0.00 0.00 312.54 297.06 98.34 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 14,770.78 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 301.88 422.83 1,134.87 0.00 0.00 307.57 273.14 19.57 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.92 -0.97 -1.00 -1.06 -1.15 -1.09 -1.07 -1.11 -1.24 -1.20 -1.10
Leverage Ratio		 1.07 1.07 1.09 1.14 1.26 1.22 1.21 1.35 1.30 1.21 1.12
Compound Leverage Factor		 1.07 1.06 1.07 1.11 1.23 1.22 1.21 1.34 1.27 1.10 0.97
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 68.86% 30.09% 21.79%
Noncontrolling Interests to Total Capital		 161.51% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 31.48% 0.00% 0.00%
Common Equity to Total Capital		 -61.51% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% -0.34% 69.91% 78.21%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 0.00 213.07 233.02 258.13 138.12 256.69 129.94 8.45 -4.66 5.53 22.70
Noncontrolling Interest Sharing Ratio		 161.51% 58.86% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 84.51% 54.08% 25.27%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 15.17 16.75 9.77 7.49 4.06 9.11 4.91 4.25 10.68 11.26 13.25
Quick Ratio		 13.10 16.02 8.94 7.28 3.92 8.90 4.66 3.83 10.61 11.16 12.89
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -11 -12 -20 -25 -51 -63 -43 -63 -104 -131 -191
Operating Cash Flow to CapEx		 -5,279.81% -8,886.79% -3,976.58% -7,628.67% -4,402.95% -1,770.44% -9,374.52% -210,905.26% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.16 0.09 0.08 0.06 0.00 0.00 0.14 0.03 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 17.49 9.77 7.16 4.15 0.00 0.00 3.68 0.60 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 2.99 -0.40 0.15 -7.01 -12 -6.23 -9.17 -5.41 -71 -85 -41
Invested Capital Turnover		 4.07 3.58 -40.82 -1.13 0.00 0.00 -2.43 -0.32 -0.02 0.00 0.00
Increase / (Decrease) in Invested Capital		 2.99 -3.39 0.55 -7.16 -4.82 5.61 -2.94 3.77 -65 -15 44
Enterprise Value (EV)		 0.00 1,397 2,201 4,412 5,464 9,285 5,764 636 17 750 1,941
Market Capitalization		 0.00 1,461 2,251 4,487 5,536 9,432 5,857 692 87 1,197 2,542
Book Value per Share		 ($37.02) $4.69 $3.02 $2.81 $2.07 $2.92 $1.70 $0.82 ($0.23) $7.04 $7.21
Tangible Book Value per Share		 ($37.02) $4.69 $3.02 $2.81 $2.07 $2.92 $1.70 $0.82 ($0.23) $7.04 $7.21
Total Capital		 36 63 50 67 60 140 84 50 269 518 715
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -33 -64 -50 -75 -72 -146 -93 -56 -339 -603 -757
Capital Expenditures (CapEx)		 0.21 0.21 0.62 0.42 1.49 4.28 0.57 0.04 -0.48 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 2.62 -1.04 -0.94 -8.08 -16 -13 -14 -8.11 -30 -49 -37
Debt-free Net Working Capital (DFNWC)		 36 62 49 66 56 133 79 48 310 554 719
Net Working Capital (NWC)		 36 62 49 66 56 133 79 48 310 554 719
Net Nonoperating Expense (NNE)		 3.37 6.36 7.86 13 22 24 20 24 169 62 8.51
Net Nonoperating Obligations (NNO)		 -33 -63 -50 -74 -72 -146 -93 -56 -339 -603 -757
Total Depreciation and Amortization (D&A)		 0.09 0.23 0.32 -0.30 -0.40 1.07 2.55 1.64 -1.35 -11 -8.09
Debt-free, Cash-free Net Working Capital to Revenue		 43.07% -22.54% -18.00% -207.84% 0.00% 0.00% -76.74% -348.18% -3,355.19% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 587.72% 1,349.59% 948.36% 1,708.64% 0.00% 0.00% 420.23% 2,043.88% 34,937.92% 0.00% 0.00%
Net Working Capital to Revenue		 587.72% 1,349.59% 948.36% 1,708.64% 0.00% 0.00% 420.23% 2,043.88% 34,937.92% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 ($1.80) ($2.13) ($2.45) ($1.52) ($1.00) ($0.99) $0.00 ($257.60) ($160.02)
Adjusted Weighted Average Basic Shares Outstanding		 599.79K 13.45M 16.72M 28.82M 29.09M 48.02M 49.36M 84.28M 0.00 47.49M 64.42M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 ($1.80) ($2.13) ($2.45) ($1.52) ($1.00) ($0.99) $0.00 ($257.60) ($160.02)
Adjusted Weighted Average Diluted Shares Outstanding		 599.79K 13.45M 16.72M 28.82M 29.09M 48.02M 49.36M 84.28M 0.00 47.49M 64.42M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 ($1.80) ($2.13) ($2.45) ($1.52) ($1.00) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 599.79K 13.45M 15.13M 20.82M 31.95M 53.37M 65.74M 65.40M 0.00 60.28M 78.54M
Normalized Net Operating Profit after Tax (NOPAT)		 -7.92 -15 -19 -32 -56 -57 -46 -59 -170 -146 -147
Normalized NOPAT Margin		 -130.16% -331.34% -372.20% -818.52% 0.00% 0.00% -245.23% -2,548.16% -19,143.58% 0.00% 0.00%
Pre Tax Income Margin		 -185.62% -468.84% -523.27% -1,140.64% 0.00% 0.00% -350.39% -3,604.59% -38,241.08% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -17.95% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Spyre Therapeutics

This table displays calculated financial ratios and metrics derived from Spyre Therapeutics' official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 - - - - - - - - - 78,540,164.00 86,841,253.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - 78,540,164.00 86,841,253.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - -0.88 -0.42
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 0.00% -100.00% -100.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -266.64% -174.88% 77.74% -84.48% 6.55% -6.40% 7.69% 76.80% -11.26% -44.76% -10.63%
EBIT Growth		 -251.27% -155.63% 79.41% -79.41% 7.78% -6.27% 4.84% 77.68% -12.24% -48.20% -8.60%
NOPAT Growth		 -139.61% -154.04% 72.28% -202.08% -33.41% -12.13% 5.01% -2.70% 6.66% 14.80% 0.71%
Net Income Growth		 -235.67% -138.07% 82.11% -72.11% 10.90% -2.09% 5.46% 83.80% -11.07% -54.12% 1.41%
EPS Growth		 0.00% 0.00% -98.53% 23.26% 86.18% 17.21% 0.00% 0.00% 0.00% 98.47% 0.00%
Operating Cash Flow Growth		 -71.09% -61.86% -274.02% 14.96% -19.86% -43.63% 25.20% -26.16% -19.84% -39.95% -50.07%
Free Cash Flow Firm Growth		 293.03% 403.77% -286.09% -132.22% -185.34% -184.16% 95.06% -590.80% -196.86% -30.77% -461.55%
Invested Capital Growth		 -1,207.92% -1,536.28% 77.20% -40.30% -20.62% -4.11% -37.20% 64.19% 51.58% 15.62% 39.39%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -64.93% 26.56% 4.66% -59.76% 16.46% 16.39% 17.28% 59.84% -300.59% -8.79% 36.78%
EBIT Q/Q Growth		 -62.75% 28.30% 7.25% -65.77% 16.34% 17.38% 16.95% 61.11% -320.66% -9.09% 39.14%
NOPAT Q/Q Growth		 -150.39% -4.05% 7.59% -25.47% -10.58% 12.55% 21.71% -35.66% -0.50% 20.17% 8.77%
Net Income Q/Q Growth		 -57.53% 30.58% 11.45% -77.74% 18.44% 20.47% 17.99% 69.54% -459.15% -10.36% 47.54%
EPS Q/Q Growth		 -1,101.16% 107.86% 149.17% 223.26% -212.26% -3,975.63% 18.08% 69.57% -393.80% 98.76% -3,894.59%
Operating Cash Flow Q/Q Growth		 10.29% 8.04% -118.09% 52.74% -26.44% -10.20% -13.58% 20.29% -20.10% -28.70% -21.80%
Free Cash Flow Firm Q/Q Growth		 -22.77% 22.74% -605.41% 93.27% -104.57% -21.04% 70.35% -840.79% 12.09% 46.68% -27.34%
Invested Capital Q/Q Growth		 -14.23% -11.68% 34.64% -68.26% 1.79% 3.60% 13.87% 56.08% -32.80% -67.97% 38.13%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.07% 100.00% 100.03% 100.00% 99.97% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 93.87% 90.82% 86.77% 93.01% 90.69% 87.34% 86.21% 67.52% 89.75% 90.80% 78.27%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -212.49% -165.81% -102.09% -91.62% -52.91% -47.04% -49.83% -38.08% -25.17% -31.11% -22.98%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -32.91% -0.38% -3.14% 14.42% -24.29% -15.58% -31.12% -22.91% -18.81% -22.71% -18.52%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -239.20% -49.68% -65.64% 0.00% -43.29% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -32 -33 -31 -39 -43 -37 -29 -40 -40 -32 -29
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -15.72% -3.98% -2.47% -9.79% -2.85% -1.39% -1.55% 6.36% -3.31% -5.68% -0.84%
Return On Investment Capital (ROIC_SIMPLE)		 -17.47% - - - -8.28% -7.77% -6.44% -8.75% -5.60% -4.76% -2.65%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -67 -48 -45 -74 -62 -51 -43 -17 -70 -76 -46
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -69 -51 -48 -77 -64 -54 -45 -18 -72 -78 -49
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 0.00 0.00 4.33 8.71 3.31 2.98 3.01 3.38 4.54 7.69 8.08
Price to Tangible Book Value (P/TBV)		 0.00 0.00 4.33 8.71 3.31 2.98 3.01 3.38 4.54 7.69 8.08
Price to Revenue (P/Rev)		 98.34 1,993.03 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 19.57 1,925.72 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.24 -1.19 -1.76 -1.32 -1.20 -1.18 -1.15 -1.15 -1.10 -1.13 -1.07
Leverage Ratio		 1.30 1.23 1.87 1.34 1.21 1.19 1.17 1.18 1.12 1.16 1.10
Compound Leverage Factor		 1.22 1.12 1.62 1.25 1.10 1.04 1.01 0.80 1.01 1.05 0.86
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 68.86% 45.59% 41.62% 47.59% 30.09% 32.29% 34.19% 34.24% 21.79% 23.23% 13.30%
Noncontrolling Interests to Total Capital		 31.48% 62.47% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -0.34% -8.05% 58.38% 52.41% 69.91% 67.71% 65.81% 65.76% 78.21% 76.77% 86.70%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -1.98 8.49 7.29 6.97 6.44 4.95 4.54 10.30 23.17 24.06 63.91
Noncontrolling Interest Sharing Ratio		 84.51% 99.77% 96.93% 115.74% 54.08% 66.89% 37.54% 39.83% 25.27% 27.02% 19.41%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 10.68 11.38 19.70 7.32 11.26 8.06 6.49 10.90 13.25 8.97 18.53
Quick Ratio		 10.61 11.32 19.26 7.20 11.16 7.99 6.34 10.51 12.89 8.71 18.09
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 33 41 -206 -14 -28 -34 -10 -96 -84 -45 -57
Operating Cash Flow to CapEx		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -71 -79 -52 -87 -85 -82 -71 -31 -41 -69 -43
Invested Capital Turnover		 -0.02 -0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -65 -74 175 -25 -15 -3.24 -19 56 44 13 28
Enterprise Value (EV)		 17 1,325 677 1,235 750 564 533 682 1,941 3,376 6,711
Market Capitalization		 87 1,371 947 1,494 1,197 973 903 1,012 2,542 3,962 7,710
Book Value per Share		 ($0.23) ($0.89) $5.43 $3.38 $7.04 $5.42 $4.97 $4.95 $7.21 $6.56 $10.99
Tangible Book Value per Share		 ($0.23) ($0.89) $5.43 $3.38 $7.04 $5.42 $4.97 $4.95 $7.21 $6.56 $10.99
Total Capital		 269 406 374 327 518 483 456 455 715 671 1,101
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -339 -485 -426 -414 -603 -565 -527 -486 -757 -741 -1,145
Capital Expenditures (CapEx)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -30 -40 -12 -51 -49 -66 -71 -28 -37 -63 -36
Debt-free Net Working Capital (DFNWC)		 310 444 414 364 554 499 456 458 719 679 1,110
Net Working Capital (NWC)		 310 444 414 364 554 499 456 458 719 679 1,110
Net Nonoperating Expense (NNE)		 31 10 7.93 30 13 7.28 7.36 -29 23 37 7.05
Net Nonoperating Obligations (NNO)		 -339 -485 -426 -414 -603 -565 -527 -486 -757 -740 -1,144
Total Depreciation and Amortization (D&A)		 -1.71 -2.42 -3.56 -3.00 -2.42 -2.64 -2.01 -1.35 -2.09 -2.06 -3.09
Debt-free, Cash-free Net Working Capital to Revenue		 -3,355.19% -5,840.99% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 34,937.92% 64,601.02% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 34,937.92% 64,601.02% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($8.61) $0.72 $0.59 $1.06 ($1.19) ($48.50) ($39.73) ($12.09) ($59.70) $0.00 ($29.56)
Adjusted Weighted Average Basic Shares Outstanding		 7.34M 36.51M 45.32M 50.89M 47.49M 60.63M 60.70M 60.78M 64.42M 0.00 85.09M
Adjusted Diluted Earnings per Share		 ($8.61) $0.72 $0.59 $1.06 ($1.19) ($48.50) ($39.73) ($12.09) ($59.70) ($0.74) ($29.56)
Adjusted Weighted Average Diluted Shares Outstanding		 7.34M 36.51M 45.32M 50.89M 47.49M 60.63M 60.70M 60.78M 64.42M 0.00 85.09M
Adjusted Basic & Diluted Earnings per Share		 ($8.61) $0.00 $0.00 $0.00 ($1.19) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 36.15M 40.28M 50.79M 51.43M 60.28M 60.35M 60.40M 77.59M 78.54M 86.84M 88.17M
Normalized Net Operating Profit after Tax (NOPAT)		 -32 -33 -31 -39 -43 -37 -29 -40 -40 -32 -29
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Spyre Therapeutics (NASDAQ: SYRE) remains a cash-rich, pre-revenue biotech, but its financials show heavy and persistent operating losses as the company continues to invest aggressively in research and development.

Over the last several years, Spyre has stayed focused on advancing its pipeline rather than generating product sales. That means investors should expect continued losses and cash burn in the near term. The good news is that the balance sheet is still very strong, with a large cash and short-term investments position that gives the company runway to keep funding development.

  • Large liquidity position: As of Q1 2026, Spyre held about $742.5 million in cash and short-term investments, which is substantial for a clinical-stage biotech.
  • Balance sheet strengthened sharply versus a year ago: Total assets rose to $764.0 million in Q1 2026 from $569.8 million in Q1 2025, largely due to financing activity and investment balances.
  • Current assets far exceed current liabilities: Q1 2026 current assets of $764.0 million compared with current liabilities of $85.2 million suggest strong near-term financial flexibility.
  • Operating capital remains manageable: Accounts payable and accrued expenses remain relatively modest compared with the company’s cash position.
  • No product revenue yet: Revenue was $0 in Q1 2026, as well as in every reported quarter shown in 2024 and 2025, so the company is still fully dependent on financing and investment income.
  • R&D spending is the main cost driver: Q1 2026 research and development expense was $60.4 million, indicating continued pipeline investment and ongoing cash usage.
  • Interest income helps offset losses somewhat: Q1 2026 interest and investment income was $7.0 million, but that is still not enough to cover operating losses.
  • Net losses remain significant: Spyre reported a Q1 2026 net loss of $69.0 million, up from $62.5 million in Q4 2025.
  • Operating cash burn is still high: Q1 2026 operating cash flow was negative $57.4 million, compared with negative $44.6 million in Q4 2025.
  • Share dilution has been material over time: The company has repeatedly raised capital, and common stock balances have climbed meaningfully across the last several years, reflecting a diluted shareholder base.

Trend summary: Spyre’s financial profile looks typical of an early-stage biotech: minimal revenue, large operating losses, and ongoing cash burn, offset by a very strong liquidity position. The biggest positive for investors is the balance sheet, which appears capable of supporting development for the foreseeable future. The biggest risk is that the company will likely need to keep spending heavily before any meaningful commercial revenue arrives.

Bottom line: SYRE looks financially stable in the near term thanks to its cash reserve, but it is still a high-risk development-stage biotech with no revenue and persistent losses. For retail investors, the story remains about pipeline execution, not earnings.

08/24/26 05:02 PM ETAI Generated. May Contain Errors.

Spyre Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Spyre Therapeutics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Spyre Therapeutics' net income appears to be on an upward trend, with a most recent value of -$155.20 million in 2025, rising from -$11.30 million in 2015. The previous period was -$208.02 million in 2024. View Spyre Therapeutics' forecast to see where analysts expect Spyre Therapeutics to go next.

Spyre Therapeutics' total operating income in 2025 was -$209.56 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $209.56 million

Over the last 10 years, Spyre Therapeutics' total revenue changed from $6.09 million in 2015 to $0.00 in 2025, a change of -100.0%.

Spyre Therapeutics' total liabilities were at $62.55 million at the end of 2025, a 31.0% decrease from 2024, and a 2,352.7% increase since 2015.

In the past 10 years, Spyre Therapeutics' cash and equivalents has ranged from $12.82 million in 2017 to $188.89 million in 2023, and is currently $85.72 million as of their latest financial filing in 2025.

Over the last 10 years, Spyre Therapeutics' book value per share changed from -37.02 in 2015 to 7.21 in 2025, a change of -119.5%.


Related Companies

Financial statements for NASDAQ:SYRE last updated on 8/4/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Someone just dumped the biggest gold fund.
Investors pulled 2.9 billion dollars from the world's largest gold fund in a single day this March, pushing to...
Behind the Markets | Sponsoredtc pixel
A $382 trillion migration and the position no one is talking about
Trump just signed a law requiring America's entire $382 trillion financial system to migrate to a new money ne...
Awesomely | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
The retirement stock I'd buy before Nvidia today
In 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...
Chaikin Analytics | Sponsoredtc pixel
Buy These Stocks Before August 31st
Keith Kaplan has invested $17 million into his own AI research platform, now used by 180,000 investors worldwi...
TradeSmith | Sponsoredtc pixel
The dollar just broke
Bloomberg research shows the U.S. dollar's share of global reserves has fallen to the lowest level this centur...
Porter & Company | Sponsoredtc pixel
The trade I’ve been waiting for since 2011
Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...
Traders Agency | Sponsoredtc pixel
Gold Explorer Sits Between Barrick’s Nevada Giants
Barrick Mining has spent decades building one of Nevada's richest gold districts, anchored by Fourmile, Goldru...
Wall Street Logic | Sponsoredtc pixel